Organogenesis (ORGO) Set to Announce Earnings on Tuesday

Organogenesis (NASDAQ:ORGO) will issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The business had revenue of $130.23 million during the quarter, compared to analysts’ expectations of $122.48 million. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Trading Up 0.6 %

Shares of ORGO opened at $3.28 on Friday. The firm has a market cap of $434.83 million, a P/E ratio of -25.23 and a beta of 1.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42. Organogenesis has a 1 year low of $1.96 and a 1 year high of $4.70. The company has a 50 day simple moving average of $2.90 and a two-hundred day simple moving average of $2.78.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.